Zacks Research Downgrades Aytu BioPharma (NASDAQ:AYTU) to Strong Sell

Aytu BioPharma (NASDAQ:AYTU) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Ascendiant Capital Markets boosted their target price on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aytu BioPharma currently has an average rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Trading Down 2.7%

AYTU stock opened at $2.16 on Wednesday. Aytu BioPharma has a twelve month low of $1.65 and a twelve month high of $3.07. The stock has a market capitalization of $23.18 million, a price-to-earnings ratio of -0.47 and a beta of 0.24. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27. The firm’s fifty day simple moving average is $2.20 and its two-hundred day simple moving average is $2.44.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The firm had revenue of $12.41 million during the quarter, compared to the consensus estimate of $12.05 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. As a group, analysts anticipate that Aytu BioPharma will post -0.73 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Arete Wealth Advisors LLC purchased a new position in Aytu BioPharma in the 1st quarter worth about $135,000. Two Sigma Investments LP boosted its position in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after buying an additional 33,701 shares during the period. Diadema Partners LP increased its position in shares of Aytu BioPharma by 12.1% during the fourth quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock worth $795,000 after acquiring an additional 33,118 shares during the period. FNY Investment Advisers LLC increased its position in shares of Aytu BioPharma by 24,207.7% during the fourth quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock worth $82,000 after acquiring an additional 31,470 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Aytu BioPharma during the third quarter valued at approximately $58,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.